Drug Profile
Measles, mumps and rubella vaccine - Zydus Lifesciences
Alternative Names: MMR vaccine - Zydus LifesciencesLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Measles vaccines; Rubella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Measles; Mumps; Rubella
Most Recent Events
- 28 Sep 2021 No development reported - Phase-III for Measles (In infants, Prevention) in India (SC) (Cadila Healthcare pipeline, September 2021)
- 28 Sep 2021 No development reported - Phase-III for Mumps (In infants, Prevention) in India (SC) (Cadila Healthcare pipeline, September 2021)
- 28 Sep 2021 No development reported - Phase-III for Rubella (In infants, Prevention) in India (SC) (Cadila Healthcare pipeline, September 2021)